CompletedNCT00456937
Escitalopram for OCD symptoms in schizophrenia
About this title
Read the official source — NCT00456937Medication studyAges 18–65Israel
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Beer YaakovSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- BeerYaakov Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Israel
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00456937
- Official title
Show the full official title
Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Beer Yaakov
Questions about this study
Who is behind this study?
The study sponsor is BeerYaakov Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Escitalopram.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Ziprasidone response in schizophrenia with or without OCD
A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders